"the Company plans to commence a Phase II trial to further validate these findings and explore additional therapeutic indications for R327. The Phase II study is expected to be across 30 patients with the aim to confirm the efficacious potential of R327 among more diverse populations, ensuring robust and comprehensive data to support its clinical development."
Sounds like they are doing another Phase I and wasting time on alternate applications to me. Still no talk of a proper phase II with actual clinical populations.
RCE Price at posting:
59.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)